Last update Nov. 28, 2024

Fremanezumab

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Fremanezumab is a humanized monoclonal antibody directed against the human calcitonin gene-related peptide involved in the pathophysiology of migraine, which is used to prevent migraines. Subcutaneous administration monthly or every 3 months.

At the date of the last update we found no published data on its excretion in breast milk.

Its very high molecular weight makes it very difficult to pass into breast milk. (Stratigakis 2023)

Its low oral bioavailability makes it difficult to pass into infant plasma from ingested breast milk since, due to its protein nature, it is degraded in the gastrointestinal tract and is not absorbed. (Anderson 2021)

Possible adverse reactions are very rare and not serious. (EMA 2023, Teva 2020)


See below the information of this related product:

  • Migraine (Safe product and/or breastfeeding is the best option.)

Alternatives

  • Erenumab (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Metoprolol (Safe product and/or breastfeeding is the best option.)
  • Nortriptyline Hydrochloride (Safe product and/or breastfeeding is the best option.)
  • Propranolol (Safe product and/or breastfeeding is the best option.)
  • Rimegepant (Safe product and/or breastfeeding is the best option.)
  • Topiramate (Safe product and/or breastfeeding is the best option.)
  • Valproate, Valproic Acid (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Fremanezumab in other languages or writings:

  • فريمانيزوماب (Arabic)
  • Фреманезумаб (Cyrillic)
  • 夫瑞奈组单抗 (Chinese)
  • Immunoglobulin G2, anti-(human α-calcitonin gene-related peptide/β-calcitonin gene-related peptide) (human-Mus musculus monoclonal TEV-48125 heavy chain), disulfide with human-Mus musculus monoclonal TEV-48125 light chain, dimer (Chemical name)
  • N02CD03 (ATC Code/s)

Groups

Fremanezumab belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Fremanezumab in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. ≈ 0 %
Molecular weight 148.000 daltons
VD 0.09 l/Kg
T½ 744 - 936 hours

References

  1. Stratigakis A, Paty D, Zou P, Zhao Z, Li Y, Zhang T. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207. Full text (link to original source) Full text (in our servers)
  2. EMA. Fremanezumab. Ficha técnica. 2023 Full text (in our servers)
  3. Anderson PO. Monoclonal Antibodies During Breastfeeding. Breastfeed Med. 2021 Aug;16(8):591-593. Abstract
  4. Teva. Fremanezumab. Drug Summary. 2020 Full text (in our servers)

Total visits

541

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Amamanta of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM